Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aveo Pharmaceuticals (AVEO)

Aveo Pharmaceuticals (AVEO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
AVEO Oncology Announces Lancet Oncology Publication of Data from Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma

AVEO Oncology (NASDAQ: AVEO) today announced that previously reported data from its Phase 3 TIVO-3 study were published in The Lancet Oncology. TIVO-3 is the Company's Phase 3 randomized, controlled, multi-center,...

AVEO : 0.75 (-1.18%)
AVEO Oncology to Present at the 31st Annual Piper Jaffray Healthcare Conference

AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 31st Annual Piper Jaffray Healthcare Conference in New York on Tuesday, December...

AVEO : 0.75 (-1.18%)
AVEO Oncology Announces Appointment of Scarlett Spring to its Board of Directors

AVEO Oncology (NASDAQ: AVEO) today announced the appointment of Scarlett Spring to its Board of Directors. Ms. Spring brings to AVEO extensive sales, commercial, and leadership experience in the biopharmaceutical...

AVEO : 0.75 (-1.18%)
AVEO Announces Presentation of Updated OS and Subgroup Data from Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma

--- Outcomes Favor Tivozanib in Patients Previously Treated With Checkpoint Inhibitors as Well as Two VEGFR-TKIs -

AVEO : 0.75 (-1.18%)
Sarepta (SRPT) Stock Down Despite New $48M Gene Therapy Deal

Sarepta (SRPT) expands its footing in the gene therapy field and signs a deal with StrideBio to develop up to eight new treatments.

AVEO : 0.75 (-1.18%)
SRPT : 109.46 (-0.45%)
ALKS : 20.95 (+1.45%)
ANIK : 57.48 (+0.75%)
AVEO Pharmaceuticals (AVEO) Q3 Earnings & Revenues Top Mark

AVEO Pharmaceuticals (AVEO) rides high on both earnings and revenue beat in the third quarter. Shares rise.

BMY : 59.95 (+0.79%)
AZN : 47.68 (+0.13%)
BAYRY : 19.1200 (-0.26%)
AVEO : 0.75 (-1.18%)
AVEO: 3Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ AVEO Pharmaceuticals Inc. (AVEO) on Tuesday reported third-quarter net income of $16.4 million, after reporting a loss in the same period a year earlier.

AVEO : 0.75 (-1.18%)
AVEO Reports Third Quarter 2019 Financial Results and Provides Business Update

AVEO Oncology (NASDAQ: AVEO) today reported financial results for the third quarter ended September 30, 2019 and provided a business update.

AVEO : 0.75 (-1.18%)
Spectrum Pharma's (SPPI) Q3 Loss Narrows, Focus on Rolontis

Spectrum Pharma (SPPI) posts a narrower-than-expected loss for the third quarter of 2019.

ALKS : 20.95 (+1.45%)
AVEO : 0.75 (-1.18%)
ANIK : 57.48 (+0.75%)
SPPI : 9.84 (+3.58%)
Global Blood's (GBT) Q3 Loss Widens, Voxelotor in Focus

Global Blood (GBT) incurs a wider-than-expected loss in the third quarter of 2019. Moreover, voxelotor for the treatment of sickle cell disease is under review in the United States.

RHHBY : 38.5700 (+0.36%)
GBT : 79.35 (+4.20%)
ALKS : 20.95 (+1.45%)
AVEO : 0.75 (-1.18%)
Zoetis (ZTS) Beats on Earnings in Q3, Reports In-Line Sales

Zoetis (ZTS) beats earnings estimates, while sales are in line in the third quarter of 2019.

ACOR : 1.71 (+0.59%)
AVEO : 0.75 (-1.18%)
ALKS : 20.95 (+1.45%)
ZTS : 121.72 (+1.34%)
Horizon Therapeutics' (HZNP) Q3 Earnings Beat Estimates

Horizon Therapeutics (HZNP) beats earnings and sales estimates in the third quarter of 2019.

ACOR : 1.71 (+0.59%)
HZNP : 32.23 (+1.16%)
AVEO : 0.75 (-1.18%)
ALKS : 20.95 (+1.45%)
AVEO Oncology and Biodesix Announce Initiation of the CyFi-2 Study, a Phase 2 Randomized Study of Ficlatuzumab in Combination with High-Dose Cytarabine vs. High-Dose Cytarabine Alone in Patients with Relapsed and Refractory AML

AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced the initiation of the CyFi-2 study, a randomized Phase 2 clinical study evaluating ficlatuzumab, AVEO's potent hepatocyte growth factor (HGF)...

AVEO : 0.75 (-1.18%)
Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q3

Ultragenyx (RARE) reports wider-than-expected loss and misses sales estimates in the third quarter of 2019.

BAYRY : 19.1200 (-0.26%)
AVEO : 0.75 (-1.18%)
RARE : 43.00 (+0.49%)
ASLN : 2.36 (-5.22%)
Intercept (ICPT) Earnings and Sales Miss Estimates in Q3

Intercept (ICPT) reports a wider-than-expected loss and misses on sales in the third quarter of 2019.

ACOR : 1.71 (+0.59%)
ICPT : 107.48 (-10.27%)
AVEO : 0.75 (-1.18%)
ASLN : 2.36 (-5.22%)
Patients Turn to Advanced Technology in Order to Combat Cancer

Over the past two decades, cancer-related deaths in the U.S. have declined significantly. As of 2015, the death rate for both men and women declined by 26% from its peak in 1991, according to the American...

ONPH : 0.0250 (unch)
INO : 2.38 (+2.36%)
REGN : 372.26 (+1.06%)
AVEO : 0.75 (-1.18%)
SLS : 4.07 (-4.91%)
NWBO : 0.2202 (-0.94%)
AVEO Oncology Announces Regulatory Update for Tivozanib in Renal Cell Carcinoma

--- Company Plans Final OS Analysis in 2Q20 -

AVEO : 0.75 (-1.18%)
AVEO Pharmaceuticals (AVEO) Earnings Expected to Grow: Should You Buy?

AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AVEO : 0.75 (-1.18%)
AVEO Sees Hammer Chart Pattern: Time to Buy?

AVEO Oncology has been struggling lately, but the selling pressure may be coming to an end soon.

AVEO : 0.75 (-1.18%)
Reata (RETA) Jumps: Stock Rises 5. 6%

Reata (RETA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

AVEO : 0.75 (-1.18%)
RETA : 199.32 (-0.12%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
CCI +0.46 , AIZ +1.17 , SBAC +0.55 , SO -0.62 , WELL -0.29
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar